NEW YORK, May 25, 2021 /PRNewswire/ — CEFALY Technology today announced the release of the new CEFALY DUAL Enhanced, the next-generation model of the dual-purpose, external Trigeminal Nerve Stimulator ...

The first dual-purpose, external trigeminal nerve stimulation device to treat and prevent acute migraine is now available over-the-counter to adults over age 18. The US Food and Drug Administration ...

Cefaly smaller anti-migraine device Previously, the external trigeminal nerve stimulator was only available with a prescription. The Food and Drug Administration (FDA) has cleared Cefaly Dual (Cefaly ...

Cefaly smaller anti-migraine device The Food and Drug Administration (FDA) approval was based on several studies that demonstrated 1 hour of use with Cefaly Acute could relieve or stop the migraine ...

Please provide your email address to receive an email when new articles are posted on . Cefaly Technology’s nerve stimulation device, when compared with sham stimulation, was more effective in ...

Cefaly Technology sprl reported results from a phase III clinical trial showing that two-hour treatment with its Cefaly Dual external trigeminal nerve stimulation (e-TNS) device is a safe and ...

NEW YORK, June 8, 2020 /PRNewswire/ -- CEFALY, the first device of its kind to receive FDA medical clearance for migraine headaches, is now expanding access to its prescribed CEFALY DUAL migraine ...

NEW YORK, Nov. 29, 2017 /PRNewswire/ -- CEFALY Technology announces today the release of two new U.S. Food and Drug Administration (FDA)-approved migraine treatment devices. Cefaly®, already the first ...

The Buy Back allows CEFALY users to trade up their device for a smaller, sleeker, device with two migraine treatment programs, rechargeable battery, and a renewed 60-day money back guarantee NEW YORK, ...

NEW YORK, June 8, 2021 /PRNewswire/ — CEFALY Technology today announced the launch of CeCe, the comprehensive, easy-to-use migraine management mobile app that helps users better understand life with ...